Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry
Leukemia. 2024 Mar 28. doi: 10.1038/s41375-024-02204-y. Online ahead of print.ABSTRACTBlast phase (BP) of chronic myeloid leukemia (CML) still represents an unmet clinical need with a dismal prognosis. Due to the rarity of the condition and the heterogeneity of the biology and clinical presentation, prospective trials and concise treatment recommendations are lacking. Here we present the analysis of the European LeukemiaNet Blast Phase Registry, an international collection of the clinical presentation, treatment and outcome of blast phases which had been diagnosed in CML patients after 2015. Data reveal the expected hetero...
Source: Hamostaseologie - March 29, 2024 Category: Hematology Authors: Annamaria Brioli Elza Lomaia Christian Fabisch Tomasz Sacha Hana Klamova Elena Morozova Aleksandra Golos Philipp Ernst Ulla Olsson-Stromberg Daniela Zackova Franck E Nicolini Han Bao Fausto Castagnetti Elzbieta Patkowska Jiri Mayer Klaus Hirschb ühl Hele Source Type: research
Integration of Extracorporeal Membrane Oxygenation into the Management of High-Risk Pulmonary Embolism: An Overview of Current Evidence
Hamostaseologie. 2024 Mar 26. doi: 10.1055/a-2215-9003. Online ahead of print.ABSTRACTHigh-risk pulmonary embolism (PE) refers to a large embolic burden causing right ventricular failure and hemodynamic instability. It accounts for approximately 5% of all cases of PE but contributes significantly to overall PE mortality. Systemic thrombolysis is the first-line revascularization therapy in high-risk PE. Surgical embolectomy or catheter-directed therapy is recommended in patients with an absolute contraindication to systemic thrombolysis. Extracorporeal membrane oxygenation (ECMO) provides respiratory and hemodynamic support...
Source: Hamostaseologie - March 26, 2024 Category: Hematology Authors: Romain Chopard Raquel Morillo Nicolas Meneveau David Jim énez Source Type: research
Post-Pulmonary Embolism Syndrome: An Update Based on the Revised AWMF-S2k Guideline
Hamostaseologie. 2024 Mar 26. doi: 10.1055/a-2229-4190. Online ahead of print.ABSTRACTIn survivors of acute pulmonary embolism (PE), the post-PE syndrome (PPES) may occur. In PPES, patients typically present with persisting or progressive dyspnea on exertion despite 3 months of therapeutic anticoagulation. Therefore, a structured follow-up is warranted to identify patients with chronic thromboembolic pulmonary disease (CTEPD) with normal pulmonary pressure or chronic thromboembolic pulmonary hypertension (CTEPH). Both are currently understood as a dual vasculopathy, that is, secondary arterio- and arteriolopathy, affecting...
Source: Hamostaseologie - March 26, 2024 Category: Hematology Authors: F Joachim Meyer Christian Opitz Source Type: research
Integration of Extracorporeal Membrane Oxygenation into the Management of High-Risk Pulmonary Embolism: An Overview of Current Evidence
Hamostaseologie. 2024 Mar 26. doi: 10.1055/a-2215-9003. Online ahead of print.ABSTRACTHigh-risk pulmonary embolism (PE) refers to a large embolic burden causing right ventricular failure and hemodynamic instability. It accounts for approximately 5% of all cases of PE but contributes significantly to overall PE mortality. Systemic thrombolysis is the first-line revascularization therapy in high-risk PE. Surgical embolectomy or catheter-directed therapy is recommended in patients with an absolute contraindication to systemic thrombolysis. Extracorporeal membrane oxygenation (ECMO) provides respiratory and hemodynamic support...
Source: Hamostaseologie - March 26, 2024 Category: Hematology Authors: Romain Chopard Raquel Morillo Nicolas Meneveau David Jim énez Source Type: research
Post-Pulmonary Embolism Syndrome: An Update Based on the Revised AWMF-S2k Guideline
Hamostaseologie. 2024 Mar 26. doi: 10.1055/a-2229-4190. Online ahead of print.ABSTRACTIn survivors of acute pulmonary embolism (PE), the post-PE syndrome (PPES) may occur. In PPES, patients typically present with persisting or progressive dyspnea on exertion despite 3 months of therapeutic anticoagulation. Therefore, a structured follow-up is warranted to identify patients with chronic thromboembolic pulmonary disease (CTEPD) with normal pulmonary pressure or chronic thromboembolic pulmonary hypertension (CTEPH). Both are currently understood as a dual vasculopathy, that is, secondary arterio- and arteriolopathy, affecting...
Source: Hamostaseologie - March 26, 2024 Category: Hematology Authors: F Joachim Meyer Christian Opitz Source Type: research
Use of Vonicog Alpha and Acquired von Willebrand Syndrome, a New Approach: A Case Report
Hamostaseologie. 2024 Mar 22. doi: 10.1055/a-2266-7984. Online ahead of print.ABSTRACTTherapeutic management of acquired von Willebrand syndrome (AVWS) can be challenging, particularly in cases of AVWS associated with monoclonal IgM such as Waldenström macroglobulinemia (WM) where several therapeutic options may be ineffective. Here, we describe the case of an 88-year-old patient who developed AVWS during follow-up for WM. The presence of a severe bleeding symptomatology not controlled by several therapies (plasma-derived von Willebrand factor, plasmapheresis) led us to introduce a supplementation with recombinant von Wil...
Source: Hamostaseologie - March 22, 2024 Category: Hematology Authors: Adeline Blandini ères Sophie Combe No émie Chanson Olivier Lambotte C écile Lavenu-Bombled Source Type: research
Use of Vonicog Alpha and Acquired von Willebrand Syndrome, a New Approach: A Case Report
Hamostaseologie. 2024 Mar 22. doi: 10.1055/a-2266-7984. Online ahead of print.ABSTRACTTherapeutic management of acquired von Willebrand syndrome (AVWS) can be challenging, particularly in cases of AVWS associated with monoclonal IgM such as Waldenström macroglobulinemia (WM) where several therapeutic options may be ineffective. Here, we describe the case of an 88-year-old patient who developed AVWS during follow-up for WM. The presence of a severe bleeding symptomatology not controlled by several therapies (plasma-derived von Willebrand factor, plasmapheresis) led us to introduce a supplementation with recombinant von Wil...
Source: Hamostaseologie - March 22, 2024 Category: Hematology Authors: Adeline Blandini ères Sophie Combe No émie Chanson Olivier Lambotte C écile Lavenu-Bombled Source Type: research
Use of Vonicog Alpha and Acquired von Willebrand Syndrome, a New Approach: A Case Report
Hamostaseologie. 2024 Mar 22. doi: 10.1055/a-2266-7984. Online ahead of print.ABSTRACTTherapeutic management of acquired von Willebrand syndrome (AVWS) can be challenging, particularly in cases of AVWS associated with monoclonal IgM such as Waldenström macroglobulinemia (WM) where several therapeutic options may be ineffective. Here, we describe the case of an 88-year-old patient who developed AVWS during follow-up for WM. The presence of a severe bleeding symptomatology not controlled by several therapies (plasma-derived von Willebrand factor, plasmapheresis) led us to introduce a supplementation with recombinant von Wil...
Source: Hamostaseologie - March 22, 2024 Category: Hematology Authors: Adeline Blandini ères Sophie Combe No émie Chanson Olivier Lambotte C écile Lavenu-Bombled Source Type: research
Intensive Care Treatment of Pulmonary Embolism: An Update Based on the Revised AWMF S2k Guideline
Hamostaseologie. 2024 Mar 18. doi: 10.1055/a-2237-7428. Online ahead of print.ABSTRACTAcute pulmonary embolism (PE) remains a significant cause of morbidity and requires prompt diagnosis and management. The prognosis of affected patients depends on the clinical severity. Therefore, risk stratification is imperative for therapeutic decision-making. Patients with high-risk PE need intensive care. These include patients who have successfully survived resuscitation, with obstructive shock or persistent haemodynamic instability. Bedside diagnostics by means of sonographic procedures are of outstanding importance in this high-ri...
Source: Hamostaseologie - March 18, 2024 Category: Hematology Authors: Uwe Janssens Source Type: research
Novel Perspectives on Thrombopoietin Receptor Agonists Applications
Hamostaseologie. 2024 Mar 18. doi: 10.1055/a-2250-9369. Online ahead of print.ABSTRACTSecond-generation thrombopoietin receptor agonists (TPO-RAs), romiplostim, eltrombopag, and avatrombopag, have been proved to be significant stimulators of megakaryopoiesis and, in the last decade, they have been incorporated in the treatment options against refractory immune thrombocytopenia in children and adults that do not respond to conventional therapy. Additionally, given their beneficial impact on hematopoiesis, they have successfully been applied in cases of non-immune thrombocytopenia, such as aplastic anemia, HCV-related thromb...
Source: Hamostaseologie - March 18, 2024 Category: Hematology Authors: Christos Stafylidis Dimitra Vlachopoulou Stavroula Syriopoulou Sevastianos Chatzidavid Nora-Athina Viniou Source Type: research
Intensive Care Treatment of Pulmonary Embolism: An Update Based on the Revised AWMF S2k Guideline
Hamostaseologie. 2024 Mar 18. doi: 10.1055/a-2237-7428. Online ahead of print.ABSTRACTAcute pulmonary embolism (PE) remains a significant cause of morbidity and requires prompt diagnosis and management. The prognosis of affected patients depends on the clinical severity. Therefore, risk stratification is imperative for therapeutic decision-making. Patients with high-risk PE need intensive care. These include patients who have successfully survived resuscitation, with obstructive shock or persistent haemodynamic instability. Bedside diagnostics by means of sonographic procedures are of outstanding importance in this high-ri...
Source: Hamostaseologie - March 18, 2024 Category: Hematology Authors: Uwe Janssens Source Type: research
Novel Perspectives on Thrombopoietin Receptor Agonists Applications
Hamostaseologie. 2024 Mar 18. doi: 10.1055/a-2250-9369. Online ahead of print.ABSTRACTSecond-generation thrombopoietin receptor agonists (TPO-RAs), romiplostim, eltrombopag, and avatrombopag, have been proved to be significant stimulators of megakaryopoiesis and, in the last decade, they have been incorporated in the treatment options against refractory immune thrombocytopenia in children and adults that do not respond to conventional therapy. Additionally, given their beneficial impact on hematopoiesis, they have successfully been applied in cases of non-immune thrombocytopenia, such as aplastic anemia, HCV-related thromb...
Source: Hamostaseologie - March 18, 2024 Category: Hematology Authors: Christos Stafylidis Dimitra Vlachopoulou Stavroula Syriopoulou Sevastianos Chatzidavid Nora-Athina Viniou Source Type: research
Intensive Care Treatment of Pulmonary Embolism: An Update Based on the Revised AWMF S2k Guideline
Hamostaseologie. 2024 Mar 18. doi: 10.1055/a-2237-7428. Online ahead of print.ABSTRACTAcute pulmonary embolism (PE) remains a significant cause of morbidity and requires prompt diagnosis and management. The prognosis of affected patients depends on the clinical severity. Therefore, risk stratification is imperative for therapeutic decision-making. Patients with high-risk PE need intensive care. These include patients who have successfully survived resuscitation, with obstructive shock or persistent haemodynamic instability. Bedside diagnostics by means of sonographic procedures are of outstanding importance in this high-ri...
Source: Hamostaseologie - March 18, 2024 Category: Hematology Authors: Uwe Janssens Source Type: research
Novel Perspectives on Thrombopoietin Receptor Agonists Applications
Hamostaseologie. 2024 Mar 18. doi: 10.1055/a-2250-9369. Online ahead of print.ABSTRACTSecond-generation thrombopoietin receptor agonists (TPO-RAs), romiplostim, eltrombopag, and avatrombopag, have been proved to be significant stimulators of megakaryopoiesis and, in the last decade, they have been incorporated in the treatment options against refractory immune thrombocytopenia in children and adults that do not respond to conventional therapy. Additionally, given their beneficial impact on hematopoiesis, they have successfully been applied in cases of non-immune thrombocytopenia, such as aplastic anemia, HCV-related thromb...
Source: Hamostaseologie - March 18, 2024 Category: Hematology Authors: Christos Stafylidis Dimitra Vlachopoulou Stavroula Syriopoulou Sevastianos Chatzidavid Nora-Athina Viniou Source Type: research
Intensive Care Treatment of Pulmonary Embolism: An Update Based on the Revised AWMF S2k Guideline
Hamostaseologie. 2024 Mar 18. doi: 10.1055/a-2237-7428. Online ahead of print.ABSTRACTAcute pulmonary embolism (PE) remains a significant cause of morbidity and requires prompt diagnosis and management. The prognosis of affected patients depends on the clinical severity. Therefore, risk stratification is imperative for therapeutic decision-making. Patients with high-risk PE need intensive care. These include patients who have successfully survived resuscitation, with obstructive shock or persistent haemodynamic instability. Bedside diagnostics by means of sonographic procedures are of outstanding importance in this high-ri...
Source: Hamostaseologie - March 18, 2024 Category: Hematology Authors: Uwe Janssens Source Type: research
